Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.

ABSTRACT: Survival rates for patients with medulloblastoma have improved in the last decades but for those who relapse outcome is dismal and new approaches are needed. Emerging drugs have been tested in the last two decades within the context of phase I/II trials. In parallel, advances in genetic profiling have permitted to identify key molecular alterations for which new strategies are being developed. We performed a systematic review focused on the design and outcome of early-phase trials evaluating new agents in patients with relapsed medulloblastoma. PubMed, clinicaltrials.gov, and references from selected studies were screened to identify phase I/II studies with reported results between 2000 and 2015 including patients with medulloblastoma aged <18 years. A total of 718 studies were reviewed an

SUBMITTER: Bautista F 

PROVIDER: S-EPMC5673921 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature